Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nova Minerals CorpNVA · Entity 6320 | Director | June 16, 2026 | June 26, 2026 |
| Pasithea Therapeutics Corp.KTTA · Entity 7685 | Member of 10% owner group | August 19, 2022 | August 26, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nova Minerals Corp
Report date June 16, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Leonite Capital LLC | 144,969 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 144,969 F1: Represents common stock and the number of shares of common stock underlying Chess Depositary Interests ("CDIs") as converted on a 1:12 common stock to CDI ratio pursuant to a scheme of arrangement, completed on June 16, 2016 (the "Scheme") between Nova Minerals Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. F2: As an officer of this entity, the reporting person has voting and investment control over the reported shares of common stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Leonite LLC | 45,881 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 45,881 F1: Represents common stock and the number of shares of common stock underlying Chess Depositary Interests ("CDIs") as converted on a 1:12 common stock to CDI ratio pursuant to a scheme of arrangement, completed on June 16, 2016 (the "Scheme") between Nova Minerals Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. F2: As an officer of this entity, the reporting person has voting and investment control over the reported shares of common stock. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.81 · Expires 2028-12-23 | IndirectBy Leonite LLC | Not disclosed |
Reported balance
Holding disclosure · report date 2026-06-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F5: The exercise price was converted from A$0.45, which reflects the 12:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on June 14, 2026. The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise. F3: 31,250 of the shares underlying these stock options are fully vested and exercisable. The remaining shares underlying these stock options will vest upon the completion of certain operational and/or sales milestones, subject to continuing services provided by the reporting person. F4: These stock options were originally rights to receive ordinary shares of the Predecessor. Under the Scheme, the stock options became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 12 ordinary shares of Predecessor to which the holder would otherwise have been entitled. F6: As an officer of this entity, the reporting person has voting and investment control over the underlying shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common stock and the number of shares of common stock underlying Chess Depositary Interests ("CDIs") as converted on a 1:12 common stock to CDI ratio pursuant to a scheme of arrangement, completed on June 16, 2016 (the "Scheme") between Nova Minerals Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX.
F2: As an officer of this entity, the reporting person has voting and investment control over the reported shares of common stock.
F3: 31,250 of the shares underlying these stock options are fully vested and exercisable. The remaining shares underlying these stock options will vest upon the completion of certain operational and/or sales milestones, subject to continuing services provided by the reporting person.
F4: These stock options were originally rights to receive ordinary shares of the Predecessor. Under the Scheme, the stock options became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 12 ordinary shares of Predecessor to which the holder would otherwise have been entitled.
F5: The exercise price was converted from A$0.45, which reflects the 12:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on June 14, 2026. The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise.
F6: As an officer of this entity, the reporting person has voting and investment control over the underlying shares of common stock.
Pasithea Therapeutics Corp.
Report date August 19, 2022 · Filed August 26, 2022
Jointly reported with Leonite Fund I, LP, Leonite Capital LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 54,644 |
Reported balance
After 2022-08-19 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-08-19 · Purchase · Acquired 54,644 · Balance 54,644 F1: The shares are held by Leonite Fund I, LP. Avi Geller is the Managing Member of Leonite Advisors LLC, which is the General Partner of Leonite Fund I, LP. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,034,702 |
Reported balance
Holding disclosure · report date 2022-08-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,034,702 F2: The shares are held by Leonite Capital LLC, of which Avi Geller serves as Chief Investment Officer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by Leonite Fund I, LP. Avi Geller is the Managing Member of Leonite Advisors LLC, which is the General Partner of Leonite Fund I, LP.
F2: The shares are held by Leonite Capital LLC, of which Avi Geller serves as Chief Investment Officer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2022 Filed Aug 26, 2022 20:30 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | PurchaseCommon Stock | 54,644 | $1.30 | $70,938.84 |
DisclosureSEC source: 0001209191-22-047714 · doc4.xml · nonDerivative · entry 1 Geller Avi · CIK 0001883076 · Member of 10% owner group Leonite Fund I, LP · CIK 0001944053 · Member of 10% owner group Leonite Capital LLC · CIK 0001824520 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 54,644 F1 · ownership.nature: The shares are held by Leonite Fund I, LP. Avi Geller is the Managing Member of Leonite Advisors LLC, which is the General Partner of Leonite Fund I, LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.